Agenda | Day One

Day One: Tuesday October 22, 2019

REGISTRATION & COFFEE

8:00

Introduction and Summary

8:15

Lung Cancer Immunotherapy

8:30

Precision Medicine: Predicting IO Efficacy

Giovanni Abbadessa

Head of Oncology Early Development

Sanofi

9:15

Advancing Biomarker Discovery and Screening with FirePlex® Technology

Ivona Kelley

Director of sales, Multiplex

abcam

9:30

Bintrafusp alfa, a new class of immunotherapy targeting simultaneously TGF-b and PD-L1 in lung cancer

Italia Grenga
Medical Director

EMD Serono, Inc.

10:00

A game of clones: Multidisciplinary science elucidates the challenge of intratumor heterogeneity in non-small cell lung cancer

Aaron Goldman

Director, R&D

Farcast Biosciences

MORNING REFRESHMENTS & SPEED NETWORKING

10:30

11:30

Understanding Immune Checkpoint TIM-3 Biology and Anti-TIM-3 Antibody for Cancer Immunotherapy

Xiaomo Jiang

Investigator III

Novartis Institutes for BioMedical Research, Immuno-Oncology

LUNCH & NETWORKING

12:00

1:00

TAKEDA: Joining the Evolution in Lung Cancer

Rachael Brake

Global Program Lead / Vice President

Takeda Oncology

1:30

Targeting lung cancer using CRISPR-Allogeneic CAR-T Cell Therapy

Mary-Lee Dequeant

Program Lead Scientist

CRISPR Therapeutics

2:00

The Plinabulin/Docetaxel combination is an Immuno/Chemo Combination with the Potential of Having Superior Efficacy, Safety and QoL over Docetaxel Monotherapy in 2nd and 3rd line NSCLC.

Ramon Mohanlal

EVP R&D, Chief Medical Officer

BeyondSpring

AFTERNOON REFRESHMENTS & NETWORKING

2:30